Form 4: Werewolf Therapeutics Director Luke Evnin Acquires Stock Options

Director Luke Evnin acquired 17,500 stock options in Werewolf Therapeutics, Inc. on May 24, 2024.

Summary

• Luke Evnin, a director of Werewolf Therapeutics, Inc., acquired 17,500 stock options on May 24, 2024.
• The options have an exercise price of $4.88.
• The options vest fully on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service as a director.
• The options expire on May 23, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continued service, suggesting an ongoing commitment to the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry, aligning their interests with those of shareholders.
• Companies like Amgen and Gilead Sciences also use stock options as part of their director compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates